Skip navigation


Sarcopenia is an age associate muscle degenerative disorder, which results in lower muscle mass and strength, leading to a decline in physical capacity. There are multiple causes for this disorder, however, decrease muscle metabolic activity including lower CoQ10 content, has been extensively characterized in this condition. BERG is initiating a Phase II clinical trial using oral BPM31510, a CoQ10 nanosuspension, that will be evaluated for impacting muscle strength, aerobic capacity, and physical function in sarcopenic patients compared to placebo controls. BERG has previously completed an oral dosing Phase I health control volunteer study of BPM31510 demonstrating safety and tolerability.

The Phase II BPM31510 sarcopenia trial will recruit 40 patients between the ages of 65-90 for this study. Patients will be treated for 28 days and subsequently analyzed for physical and metabolic fitness. Additionally, BERG will utilize its Interrogative Biology® platform to assess biomarker changes associated with treatment in both muscle and blood samples.